Linvoseltamab-Gcpt 5 mg/2.5 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 5 mg/2.5 mL

Reference Brands: Lynozyfic (USA/EU)

Category: Oncology Cancer Care

Linvoseltamab‑gcpt is a bispecific T‑cell engager antibody that binds to CD3 on T‑cells and BCMA on malignant plasma (myeloma) cells. This facilitates T‑cell activation and directs T cells to kill multiple myeloma cells. Lynozyfic is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, im‑modulatory agent and an anti‑CD38 antibody).

Product Description:

Linvoseltamab is a bispecific antibody that links CD3 on a T cell to BCMA on a myeloma cell. BCMA is a near-ideal target: it is expressed on malignant plasma cells and almost nowhere else, which is why it has become the focus of the newest myeloma therapies. Unlike CAR-T approaches directed at the same antigen, this is an off-the-shelf product requiring no cell collection, no manufacturing slot and no bridging therapy while a patient waits.

It is indicated for relapsed or refractory multiple myeloma in adults who have had at least four prior lines including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody — a population with very limited options. It is given intravenously with a step-up schedule to mitigate cytokine release syndrome, which occurs in a majority of patients and is usually confined to the first cycle. Neurotoxicity, serious infection and prolonged hypogammaglobulinaemia requiring immunoglobulin replacement also occur.

Sourcing notes. Originator biologic under patent, recently approved and not yet registered everywhere — confirm status per destination. Cold chain at 2–8 degrees, do not freeze or shake. The receiving centre must be able to monitor inpatients through the step-up doses.